CommercialBilling CodesMedium impact
11.09.02r, Gender-Affirming Interventions
Independence Blue Cross·PA · Psychiatry, Endocrinology, General Surgery +2 more·Medical Policy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued medical policy 11.09.02t for gender-affirming interventions, which supersedes version 11.09.02r. The policy underwent an annual review on 12/10/2025 and includes a HCPCS code update effective 07/01/2025 for J1954 (puberty-suppressing hormone). The policy establishes medical necessity criteria for coverage of puberty-suppressing hormones, hormone-replacement therapy, and bilateral mastectomy for individuals with gender dysphoria or gender diversity.
Action Required
Before 07/01/2025: Billing team must update billing software to recognize HCPCS code J1954 revision and ensure all gender-affirming intervention claims include proper documentation. Verify that claims for puberty-suppressing hormones (J1954, J1380, J1050, J1071, J1072, J1073) require: (1) behavioral health provider letter meeting specified criteria (master's degree minimum, specific documentation elements); (2) verification that patient meets medical necessity criteria (Tanner Stage 2+ for puberty suppressants, persistent documented gender dysphoria/incongruence for hormone replacement); (3) appropriate ICD-10 codes (F64.0, F64.2, F64.8, F64.9, F64.A, Z87.8901-Z87.8904); and (4) confirmation that oral and self-administered hormones are NOT covered under medical benefit. Update prior authorization workflows to require behavioral health provider letters for surgical interventions (bilateral mastectomy). Notify providers that cosmetic services are excluded. Failure to obtain proper documentation and prior authorization will result in claim denials.